Category: GOVERNMENT

DEA Reclassifies Plant-Derived Marijuana Medicine To Schedule V

Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), has been reclassified today by the US Drug Enforcement Administration to Schedule V — the lowest restriction classification available under federal law. The rescheduling change is only specific to Epidiolex, and does not amend the schedule I status of either whole-plant cannabis of CBD.

Congressional Committee Approves Legislation To Facilitate Clinical Cannabis Research

Members of the House Judiciary Committee voted today in favor of legislation (HR 5634: The Medical Cannabis Research Act of 2018) to facilitate federally-approved clinical trials assessing the efficacy of whole-plant cannabis. The vote marks the first time that lawmakers have ever decided in favor of easing existing federal restrictions which limit investigators ability to clinically study marijuana in a manner similar to other controlled substances.